This DP3 grant, offered by the Diabetes Research Department, encourages researchers with access to clinical nuclear molecular imaging facilities to identify novel pancreatic islet beta cell imaging agents. The initiative involves screening existing, human-approved PET or SPECT neuroimaging agents. Monitoring beta cell mass is crucial for understanding human diabetes progression, but current methods are insufficient. Human pancreatic islet beta cells, distinct from rodent models, possess similar neurotransmitter systems to the brain. Thus, directly evaluating existing human neuroimaging agents in human subjects and tissues offers a cost-effective approach to discover tools for in vivo beta cell study, advancing diabetes research.
Opportunity ID: 242577
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-13-024 |
| Funding Opportunity Title: | Harvesting the Neuroimaging Cornucopia for Pancreatic Islet Imaging Reagents for Diabetes Research (DP3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.286 — Discovery and Applied Research for Technological Innovations to Improve Human Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 13, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Feb 20, 2014 |
| Current Closing Date for Applications: | Feb 20, 2014 |
| Archive Date: | Mar 23, 2014 |
| Estimated Total Program Funding: | $1,000,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) For profit organizations other than small businesses State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) encourage DP3 applications from institutions/organizations to allow researchers with access to major clinical nuclear molecular imaging facilities to screen their libraries of existing positron emission tomography (PET) or single photon emission computed tomography (SPECT) neuroimaging agents that are already approved for use in human subjects research in order to find tools to enhance in vivo study of the beta cells of the human pancreatic islet. Diabetes ensues with the loss or dysfunction of beta cells and the inability to monitor their mass is an enormous barrier to understanding the natural history of human diabetes or the course of disease in an individual patient. Because human pancreatic islet beta cells are distinct from those of rodent models of diabetes and yet have many of the neurotransmitter systems found in the human brain, screening of existing human neuroimaging agents directly in human subjects and human tissues may be a cost-efficient way to identify promising beta cell imaging agents. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-13-024.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | Forms-C | PKG00185171 | Jan 20, 2014 | Feb 20, 2014 | View |
Package 1
Mandatory forms
242577 RR_SF424_2_0-2.0.pdf
242577 PHS398_ResearchPlan_2_0-2.0.pdf
242577 RR_KeyPersonExpanded_2_0-2.0.pdf
242577 RR_OtherProjectInfo_1_3-1.3.pdf
242577 PerformanceSite_2_0-2.0.pdf
Optional forms
242577 PHS398_CumulativeInclusionReport-1.0.pdf
242577 PlannedReport-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
